| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $21,474,461 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21HD117520 | Evaluating causes for failure to thrive in a Noonan-like syndrome with loose anagen hair (NSLH) patients using NSLH vertebrate model | 000 | 1 | NIH | 11/5/2024 | $231,000 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES033767 | Phthalate-Induced Dysregulation of Prostaglandin and Angiogenic Function During Ovulation in Women | 000 | 4 | NIH | 11/5/2024 | $442,197 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31DA055445 | Claustrum serotonin and spike-timing plasticity associated with cognitive deficits after cocaine | 000 | 2 | NIH | 10/16/2024 | $37,511 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM131807 | Hedgehog Signaling in Development and Metabolism | 003 | 6 | NIH | 1/31/2025 | $415,800 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI180274 | Molecular mechanisms of Helicobacter pylori trans-kingdom DNA conjugation | 000 | 2 | NIH | 11/27/2024 | $172,539 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG061111 | Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArTâHS) | 000 | 5 | NIH | 1/23/2025 | $605,800 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG070279 | Cognitive Aging Trajectories in Survivors of Trauma | 000 | 3 | NIH | 1/23/2025 | $125,590 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AI175220 | Chlamydia type III effectors affecting the host actin-based cytoskeleton | 000 | 3 | NIH | 1/22/2025 | $543,958 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K99AG084892 | Gabapentin prescription and health-related outcomes in older adults | 000 | 2 | NIH | 11/27/2024 | $89,895 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS135089 | Cannabidiol (CBD) as a Potential Therapeutic for Experimental Subarachnoid Hemorrhage | 000 | 2 | NIH | 11/15/2024 | $191,250 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG066724 | Novel gastrocnemius muscle characteristics in peripheral artery disease patients associated with impaired functional performance | 001 | 5 | NIH | 11/28/2024 | $272,549 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL166225 | Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis | 000 | 3 | NIH | 12/9/2024 | $598,473 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES032396 | A university-community partnership to reduce exposure to disinfection byproducts in Appalachia | 000 | 5 | NIH | 12/9/2024 | $102,458 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL175979 | PPARgamma Coregulators in Rosiglitazone-Induced Cardiovascular Disease | 001 | 1 | NIH | 12/5/2024 | $0 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG070830 | Contributions of astrocyte RelA signaling in aging-related neurodegenerative sequelae following TBI | 000 | 5 | NIH | 12/19/2024 | $598,802 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM130349 | Functional Analysis of Programmed Genome Rearrangement | 001 | 6 | NIH | 1/17/2025 | $430,737 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21ES036036 | R21-UKY East Palestine Train Derailment Health Tracking Study | 000 | 2 | NIH | 12/30/2024 | $196,666 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01HL177045 | Circadian Regulation of Cardiomyocyte Size and Function | 000 | 1 | NIH | 12/30/2024 | $143,829 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AI155545 | Anti-inflammatory functions for non-transcriptional IRF3 | 000 | 4 | NIH | 1/3/2025 | $407,851 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA053070 | Functional and Genomic Signatures of Escalated Fentanyl Use | 000 | 5 | NIH | 12/19/2024 | $572,466 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25ES027684 | Summer Research in Environmental Health Sciences | 000 | 8 | NIH | 11/22/2024 | $9,154 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL173026 | Investigating the Role of HDL-Associated Serum Amyloid A in Sepsis-Induced Acute Lung Injury and Mortality | 000 | 1 | NIH | 12/30/2024 | $699,385 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS116068 | Macrophage Depletion Therapy for Spinal Cord Injury | 000 | 5 | NIH | 11/13/2024 | $555,534 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL172844 | Mechanisms of Thrombosis in SARS CoV-2 Infection | 000 | 1 | NIH | 1/10/2025 | $503,637 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R03EB037115 | In situ forming implant drug delivery for non-addictive post-operative analgesia | 000 | 1 | NIH | 1/8/2025 | $75,007 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R03MH136192 | The Role of Social Supports in Mitigating the Effects of Adverse Childhood Experiences on Adolescent Psychopathology | 000 | 2 | NIH | 2/13/2025 | $65,025 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01HL149984 | Pharmacological Mechanistic Insights into Thoracic Aortic Aneurysm | 000 | 5 | NIH | 11/29/2024 | $162,000 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM156952 | Gene regulatory network plasticity in social behavior | 000 | 1 | NIH | 1/6/2025 | $365,000 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R37CA278989 | Mechanistic and structural insights into a new pro-metastatic collagen glucosyltransferase | 000 | 2 | NIH | 1/6/2025 | $461,637 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P20GM121327 | University of Kentucky Center for Cancer Metabolism | 001 | 9 | NIH | 12/23/2024 | $2,060,688 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082142 | MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | 000 | 3 | NIH | 12/6/2024 | $600,292 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K08DK124566 | Muscle bone interaction and its role in diabetic bone disease of Type I diabetes | 000 | 5 | NIH | 12/20/2024 | $164,517 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01DK128022 | Elucidating Molecular Mechanisms Linking Fructose to Cholesterol Metabolism | 000 | 4 | NIH | 12/20/2024 | $148,186 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084282 | Using the gut microbiome to treat skeletal muscle atrophy | 000 | 1 | NIH | 1/27/2025 | $458,907 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL175979 | PPARgamma Coregulators in Rosiglitazone-Induced Cardiovascular Disease | 000 | 1 | NIH | 12/5/2024 | $34,896 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL170972 | Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction | 000 | 2 | NIH | 12/5/2024 | $34,966 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23MH126211 | A Precision Medicine Approach to Target Engagement for Emotion Regulation | 000 | 4 | NIH | 1/27/2025 | $110,027 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R24OD010435 | Research Resources for Model Amphibians | 000 | 23 | NIH | 2/14/2025 | $406,029 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 000 | 4 | NIH | 2/14/2025 | $224,101 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG070952 | Dynamic GABA and Glutamate Neurotransmission in Alzheimer’s Disease and Aging | 000 | 3 | NIH | 3/4/2025 | $596,811 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA251663 | Targeting Mitochondrial Redox Capacity to Overcome Cancer Subtype that Regrowth After Radiation | 000 | 5 | NIH | 3/3/2025 | $314,989 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA259580 | Defining the Critical Function and Regulation of NNMT in Breast Cancer Progression and Metastasis | 000 | 5 | NIH | 3/4/2025 | $352,538 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA284532 | Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | 000 | 2 | NIH | 2/17/2025 | $362,672 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL168085 | Development of a Percutaneous Double Lumen Cannula-Based Cavopulmonary Assist System Toward Clinical Application | 000 | 2 | NIH | 2/25/2025 | $596,904 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P50MD019476 | UK ASCEND (Achieving Success in Community-Engaged research to elimiNate Disparities) | 000 | 2 | NIH | 2/18/2025 | $540,550 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 000 | 11 | NIH | 2/24/2025 | $288,205 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK124774 | Circadian Regulation of Metabolic Risk in Mice and Women: Role of Estrogen and Time-Restricted Feeding | 000 | 5 | NIH | 2/25/2025 | $509,460 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 000 | 2 | NIH | 3/6/2025 | $596,055 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 South Limestone | Lexington | KY | 40526-0001 | FAYETTE | USA | H7600719 | Ryan White Part C Outpatient EIS Program | 00 | 24 | HRSA | 3/6/2025 | $162,498 |
|
